موافقات الدواء

Momelotinib is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia, intermediate or high-risk myelofibrosis who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus Kinase (JAK) inhibitor nave or have been treated with ruxolitinib.